> Our serological validation was chiefly limited by use of excess serum specimens from a mostly hospitalized population known to be very recently infected with

> Our serological validation was chiefly limited by use of excess serum specimens from a mostly hospitalized population known to be very recently infected with SARS-CoV-2. Basically, this test may not be as sensitive (or patients may not seroconvert as often) with mild or asymptomatic cases. To avoid this problem we should run a two-part study, the first part a PCR test of a large random sample, and the second part a follow-up to measure antibodies. Has anyone heard about a study of this kind that may be in progress?